Loading condition report…
Loading condition report…
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Alcohol use disorder · Alcohol dependence · Alcohol withdrawal
registered studies · not a treatment claimAlcohol use disorder · Alcohol dependence · Alcohol withdrawal
registered studies · not a treatment claimAlcohol use disorder · Alcohol dependence
Alcohol use disorder
document association · not a treatment claimAlcohol use disorder · Alcohol dependence · Alcohol withdrawal
document association · not a treatment claimAlcohol use disorder
document association · not a treatment claimAlcohol use disorder
document association · not a treatment claimHow treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 8 of 8 unique registrations. 8 pattern memberships are preserved as badges; counts may overlap.
Alcohol addiction (AD) is a chronic relapsing disorder with currently limited pharmacological treatment options. Alcohol craving, a hallmark symptom of AD that drives relapse in patients, is only insufficiently treated by existing medication.
Open study recordDetermine the change in the Timeline Follow-back (TLFB) assessment of alcohol consumption and the change in percent Carbohydrate Deficient Transferrin (CDT) in serum, to evaluate the therapeutic potential of CBD in the management of patients with alcohol dependence who are seeking treatment to achieve abstinence.
Open study recordTo assess the effect of either 800mg or 1200mg oral CBD in addition to background treatment with 50mg oral Naltrexone on the reduction of alcohol craving compared to the effects of a placebo in addition to standard treatment with 50mg oral Naltrexone.
Open study recordDetermine the change in the Timeline Follow-back (TLFB) assessment of alcohol consumption and the change in percent Carbohydrate Deficient Transferrin (CDT) in serum, to evaluate the therapeutic potential of CBD in the management of patients with alcohol dependence who are seeking treatment to achieve abstinence.
Open study recordDetermine the change in the Timeline Follow-back (TLFB) assessment of alcohol consumption and the change in percent Carbohydrate Deficient Transferrin (CDT) in serum, to evaluate the therapeutic potential of CBD in the management of patients with alcohol dependence who are seeking treatment to achieve abstinence.
Open study recordResearch frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 29 directly scoped registrations.
20 enrolled
Open study record45 enrolled
Open study record36 enrolled
Open study record95 enrolled
Open study record101 enrolled
Open study record0 enrolled
Open study record150 enrolled
Open study record118 enrolled
Open study record150 enrolled
Open study record108 enrolled
Open study record180 enrolled
Open study record150 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 19,009 records · source sync still in progress
PROJECT NARRATIVE Understanding the complex, bidirectional interrelationship mechanisms between sleep and substance use disorders is a foundational step in the pursuit of prevention and novel therapeutics. This project contributes in an innovative way to the understanding of how sleep disturbance is associated with neurocircuit dysfunction and may exacerbate withdrawal symptoms in those with co-occurring cannabis and alcohol use disorder. In addition, this project aims to examine if objective sleep disturbance can be modified using a behavioral intervention and subsequently improve neurocircuit dysfunction and withdrawal severity.
Research Narrative As access to cannabis has increased dramatically, it is imperative to understand how to approach cannabis use among individuals with alcohol use disorder (AUD) who also use cannabis. The proposed research will compare the effects of a harm reduction intervention (instruction to switch from a high THC product to a low THC/high CBD) product versus a no intervention control condition (continue to use THC like you normally do) in a sample of cannabis users who wish to reduce or quit drinking. If the hypotheses of the proposed research are supported, the dissemination of the research would have an immediate public health impact by educating individuals and health care providers about the relative benefits of switching from high potency THC products to a product with lower THC and higher CBD.
PROJECT NARRATIVE This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, we will conduct a clinical trial in which we administer CBD to fifty individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms.
PROJECT NARRATIVE This project is a critical step in assessing the effects of cannabidiol as a candidate medication treatment for youth alcohol use disorder. Medications could help bolster psychosocial interventions for youth struggling with alcohol use problems and reduce the likelihood of transitioning into severe, persisting alcohol use disorder in adulthood, thereby significantly reducing costs to the healthcare system and society.
Combat-exposed Veterans and military personnel have a higher risk of developing posttraumatic stress disorder (PTSD) than civilians and often use alcohol to alleviate their PTSD symptoms, which can render them more susceptible to alcohol use disorders (AUDs). It is well documented that individuals with PTSD comorbid with AUD have more intense alcohol cravings and faster relapse during withdrawal than those with AUD only, making Veterans uniquely suspectible. Recently, the cannabinoid system has emerged as a signaling pathway common to stress and alcohol dependence and withdrawal. Therefore, it is important to examine this pathway in the PTSD and alcohol dependence and withdrawal comorbidity condition and to evaluate innovative therapeutic strategies that target the cannabinoid system. These therapeutic strategies may help to reduce anxiety behavior and alcohol craving during rehabilitation of affected Veterans. Therefore, this project is highly relevant to the VA mission for patient care and rehabilitation.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
Combat-exposed Veterans and military personnel have a higher risk of developing posttraumatic stress disorder (PTSD) than civilians and often use alcohol to alleviate their PTSD symptoms, which can render them more susceptible to alcohol use disorders (AUDs). It is well documented that individuals with PTSD comorbid with AUD have more intense alcohol cravings and faster relapse during withdrawal than those with AUD only, making Veterans uniquely suspectible. Recently, the cannabinoid system has emerged as a signaling pathway common to stress and alcohol dependence and withdrawal. Therefore, it is important to examine this pathway in the PTSD and alcohol dependence and withdrawal comorbidity condition and to evaluate innovative therapeutic strategies that target the cannabinoid system. These therapeutic strategies may help to reduce anxiety behavior and alcohol craving during rehabilitation of affected Veterans. Therefore, this project is highly relevant to the VA mission for patient care and rehabilitation.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
In alcohol dependent individuals, abstinence from drinking is accompanied by negative emotional symptoms such as anxiety that can be relieved by renewed drinking. This form of "self-medication" is believed to be a driving force for continued excessive alcohol consumption. Preliminary evidence indicates that dysfunctional endocannabinoid signaling contributes to withdrawal-related anxiety and excessive alcohol consumption, and the overall goal of this project is to investigate the therapeutic benefit provided by selective endocannabinoid clearance inhibitors for the treatment of alcohol dependence.
Showing 12 of 35 frozen records. Browse the complete set →
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
FAERS/AEMS reports are post-market signals. Counts do not establish causality or incidence and may contain duplicates or reporting bias.
Regulatory records
Active ingredient: NABILONE, cesamet
Route / form: ORAL, CAPSULE
Status: FDA approved · US
Record type: Regulatory product record
Preserved context: See the local medicine record for current source-backed regulatory and study context.
INDICATIONS AND USAGE Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness.
Open local regulatory record →A catalog record is not, by itself, an efficacy claim.Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D000437 using Medical Subject Headings 2026.
44,938 source identifiers verified · snapshot record 2ebe7410231e...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 17,191 frozen records. Browse the complete set →